Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.275 +0.025 (+2.00%)
Streaming Delayed Price Updated: 12:25 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types ↗
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial. 
Via Benzinga
News headline image
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's going on in today's after hours session ↗
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future ↗
Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited catalysts and pipeline challenges. 
Via Benzinga
News headline image
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.